Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Docetaxel cytotoxicity is enhanced by inhibition of the Raf/MEK/ERK signal transduction pathway.

× No keyword cloud information.

5 in total

1. Inhibiting ERK/Mnk/eIF4E broadly sensitizes ovarian cancer response to chemotherapy.

Authors: S Liu; J Zha; M Lei
Journal: Clin Transl Oncol Date: 2017-08-01 Impact factor: 3.405

2. Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer.

Authors: Doris Posch; Hannah Fuchs; Gabriela Kornek; Anja Grah; Johannes Pammer; Marie-Bernadette Aretin; Thorsten Fuereder
Journal: Sci Rep Date: 2016-09-06 Impact factor: 4.379

3. [Sequence-dependent effect of docetaxel with gefitinib on the proliferation and signal protein expression of human lung adenocarcinoma cell SPC-A1].

Authors: Wenying Zhang; Weimin Zhang; Lin Wang; Jingxian Zheng; Feng Xiao
Journal: Zhongguo Fei Ai Za Zhi Date: 2011-05

4. MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC.

Authors: Derek A Franklin; Joe T Sharick; Paula I Ericsson-Gonzalez; Violeta Sanchez; Phillip T Dean; Susan R Opalenik; Stefano Cairo; Jean-Gabriel Judde; Michael T Lewis; Jenny C Chang; Melinda E Sanders; Rebecca S Cook; Melissa C Skala; Jennifer Bordeaux; Jehovana Orozco Bender; Christine Vaupel; Gary Geiss; Douglas Hinerfeld; Justin M Balko
Journal: JCI Insight Date: 2020-08-06

5. Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent/metastatic head and neck cancer.

Authors: Hannah Fuchs; Johannes Pammer; Christoph Minichsdorfer; Doris Posch; Gabriela Kornek; Marie-Bernadette Aretin; Thorsten Fuereder
Journal: Med Oncol Date: 2018-02-07 Impact factor: 3.064

5 in total